Northpond and Cowen lead Series A round for Aro Biotherapeutics

Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, has raised $88 million in Series A financing.

Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, has raised $88 million in Series A financing. Northpond Ventures and Cowen Healthcare Investments led the round.

Source: Press Release